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Background: Sleep disturbances are a hallmark of posttraumatic stress disorder (PTSD),
yet few studies have evaluated the role of dysregulated endogenous melatonin secretion
in this condition.
Methods: This study compared the sleep quality and nocturnal salivary melatonin profiles
of Canadian Armed Forces (CAF) personnel diagnosed with PTSD, using the Clinician
Administered PTSD Scale (CAPS score ≥50), with two healthy CAF control groups;
comprising, a “light control” (LC) group with standardized evening light exposure and
“normal control” (NC) group without light restriction. Participants were monitored for
1-week using wrist actigraphy to assess sleep quality, and 24-h salivary melatonin levels
were measured (every 2h) by immunoassay on the penultimate day in a dim-light (< 5 lux)
laboratory environment.
Results: A repeated measures design showed that mean nocturnal melatonin
concentrations for LC were higher than both NC (p = .03) and PTSD (p = .003) with no
difference between PTSD and NC. Relative to PTSD, NC had significantly higher melatonin
levels over a 4-h period (01 to 05 h), whereas the LC group had higher melatonin levels
over an 8-h period (23 to 07 h). Actigraphic sleep quality parameters were not different
between healthy controls and PTSD patients, likely due to the use of prescription sleep
medications in the PTSD group.
Conclusions: These results indicate that PTSD is associated with blunted nocturnal
melatonin secretion, which is consistent with previous findings showing lower melatonin
after exposure to trauma and suggestive of severe chronodisruption. Future studies
targeting the melatonergic system for therapeutic intervention may be beneficial for
treatment-resistant PTSD.
Keywords: sleep disturbance, melatonin, post-traumatic stress disorder, dim light melatonin onset,
circadian, saliva
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INTRODUCTION

sun sets, melatonin production begins to rise with a peak near
the midpoint of the dark interval (33). This phenomenon is
called dim light melatonin onset (DLMO) (34). After sunrise,
the nocturnal surge of melatonin ends; called melatonin offset
(MelOff) (35, 36). Recent investigations have highlighted the
ubiquitous influence of circadian timing and melatonin in
almost all physiologic functions (35, 36). An altered sleepwake cycle has been correlated with physiological imbalances
that are linked to the development of various mental disorders
and melatonin-based chronobiologic interventions may
prove efficacious for treatment of circadian disruption in
PTSD (37–39). Moreover, mounting evidence suggests that
strong antioxidant activities and diverse immunomodulatory
properties of melatonin as potential protective roles in diverse
neuropsychiatric disorders including PTSD (38, 40). The aim
of the current research was to test the hypothesis that militaryrelated PTSD with clinically endorsed “sleep difficulties” is
associated with decreased production of endogenous melatonin
and possible chronodisruption, relative to healthy military
controls. We investigated whether salivary melatonin levels
and sleep patterns are different in Canadian Armed Forces
(CAF) military personnel with PTSD when compared to
matched healthy CAF members as controls, by assessing daily
sleep quality for 7 days and measuring 24-h salivary melatonin
secretion on the eighth day of study.

Degraded mental health remains prevalent and impactful in
military personnel (1, 2), and has significant implications
for operational readiness and force sustainability (3–5).
Posttraumatic stress disorder (PTSD) is a chronic and
disabling neuropsychiatric condition that develops in a
subset of individuals after exposure to traumatic or extremely
stressful events (6). According to the Diagnostic and
Statistical Manual 5th Edition (DSM-5) criteria (7), PTSD is
characterized by an array of affective, cognitive and attention
disturbances, that manifest as four clusters of symptoms. By
the very nature of their profession, military personnel can be
exposed to traumatic stressors (i.e., combat, injury, witnessing
suffering, and/or death) and consequently are at high risk for
developing PTSD following war-zone deployment(s) (8–11).
Effective prevention and treatment strategies for militaryrelated PTSD are hampered by a lack of understanding of
the basic pathophysiologic mechanisms/markers across
different stages of disease progression (12–14). Moreover, the
management of treatment-resistant PTSD presents a complex
clinical challenge (15, 16) and many patients may continue
to endure a heavy symptom burden, even despite the best
available treatments (17).
Sleep disturbances are considered hallmark symptoms of
PTSD and may contribute significantly to the development
and maintenance of PTSD (18). Indeed, sleep complaints
remain the most common presenting symptoms and subjective
complaints among people with PTSD (19). Healthy sleep is
defined by predictable, sufficient restorative sleep (20). These
needs are disrupted in combat-exposed soldiers and veterans
with PTSD (21, 22). According to the DSM-5, sleep disturbance
and recurrent trauma-content nightmares are core hyperarousal
and re-experiencing symptoms of PTSD (23). About 70% of
individuals with PTSD have co-occurring sleep problems,
reporting greater trouble initiating and maintaining sleep, early
morning awakening, nightmares, nocturnal panic attacks, and
other parasomnias (24). Distressed awakenings and inability to
return to sleep, with or without recalled trauma nightmares, may
be the most common symptom motivating combat veterans to
seek treatment for PTSD (22, 25).
Relevant preclinical and clinical literature has neglected
the potentially important pathophysiological role of circadian
rhythm disruption in PTSD (26). Despite considerable research
examining the association between sleep and PTSD (27), few
studies have attempted to identify specific underlying biological/
circadian mechanisms that may account for this relationship
(28, 29). McFarlane et al. (30) found lower urinary melatonin
levels after trauma exposure, predicting a higher risk for PTSD,
while van Liempt et al. (31) reported undisturbed nocturnal
plasma melatonin profiles in PTSD patients. Other evidence
underscores a key function of the melatonergic system in
sleep and chronodisruption following trauma exposure and its
probable role in a chronically dysregulated circadian network in
PTSD (26, 32).
For healthy individuals who sleep at night, daytime
endogenous melatonin levels are barely detectable. Once the
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MATERIALS AND METHODS
Study Design

We conducted a retrospective cohort study investigating relationships
between sleep disturbances and salivary melatonin levels in CAF
military personnel with PTSD and matched healthy CAF members
as controls.

Participants and Clinical Procedures

Volunteers included treatment-seeking CAF members (N = 7)
with clinically endorsed “sleep difficulties,” aged 31 to 45 years
with mean age and standard deviation of 37.57 ± 6.05. These
participants had experienced a self-reported deploymentrelated trauma with a “current” diagnosis of PTSD by a licensed
CFHS (Canadian Forces Health Services) and/or Department of
Veteran Affairs of Canada (VAC) psychiatrist. Each diagnosis was
based upon a comprehensive psychiatric examination, according
to criteria outlined by the Clinician Administered PTSD Scale
(CAPS) for the DSM-5, including CAPS score ≥50 (41). Healthy
CAF members (N = 14) who had not been diagnosed with any
DSM-5 condition (including PTSD) at any point in their lives
or reported sleep disorders, served as controls. Controls were
stratified according to those whose data was collected under
either naturalistic diurnal environmental conditions (NC;
N = 7) aged 22 to 52, with mean age and standard deviation of
35.25 ± 9.38 or idealized sleep-wake conditions with strictly
controlled nocturnal light-exposure, as previously described
(light controlled (LC); N = 7) aged 23 to 43 with mean age and
standard deviation of 29.43 ± 8.50 (42). A comparison of all
participants is presented in Table 1.
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data collection period. The subjects were allowed to get up from
their chairs to access the washrooms or socialize for about 100 min
of each 2-h block. However, they remained in ambient lighting
levels of less than 5 lux throughout the 24-h data collection. All
subjects returned to semi-recumbent posture in their lounge chairs
at least 15 min prior to each sample. The saliva was collected in test
tubes (Salivette®, Starstedt Inc. Montreal, QC). For each sample, the
subjects chewed the cotton plug for 45 s, and then stopped chewing
with the plug still in their mouth to allow the saliva to absorb for
another 45 s. The participants were required to remain awake from
0900 h until 2300 h, after which they were allowed to sleep. If asleep,
they were awakened in the 15 min prior to the next sample. Meals
were provided in three 1-h windows as follows: 1) lunch 12–13 h, 2)
dinner 17–18 h, and 3) breakfast 07–08 h.
The saliva samples were analyzed for melatonin content
using the Buhlmann Laboratories (Schönenbuch, Switzerland)
enzyme-linked immunosorbent assay (ELISA) kits and used
the Kennaway G280 anti-melatonin antibody. Each subject’s
samples were analyzed in duplicate on the same ELISA plate. The
reported intra- and inter-assay coefficients of variation for the
kits were 12.6 and 22.9% respectively, with a limit of detection
(sensitivity) of 0.5 pg/ml. Using the same melatonin collection
protocol and melatonin ELISA, we compared the current
melatonin and sleep findings to melatonin and sleep data from
a cohort of seven military personnel while they were deployed
to the most northerly manned outpost in the world (CFS Alert)
during arctic summer (i.e., 24/7 sunlight) (42). This was the LC
group. The PTSD group was assessed at Canadian Forces Base
(CFB) Gagetown (Fredericton, New Brunswick). The normal
control (NC) group were assessed at DRDC—TRC.
The distribution of military occupation specialties among
the PTSD and healthy control groups are illustrated in
Supplementary Data Table 1.
Of the seven PTSD participants, three were taking the
sleeping medication zopiclone, one was taking lorazepam (an
anxiolytic known to facilitate sleep), one was taking oxazepam
(another anxiolytic known to facilitate sleep), and one was on
both zopiclone and trazodone (an antidepressant known to
facilitate sleep). Essentially, six of the seven PTSD participants
were on medications to facilitate sleep (see Supplementary Data
Table 1). None of the control participants (NC or LC) were on
any medication. The gender split and age demographics of all
three participant groups are illustrated in Table 1.

TABLE 1 | Demographic characteristics of study participants.
Group

Sample size
(N)

% Male

Mean age ± SD
(range)

PTSD
NC
LC

7
7
7

71.4
85.7
57.1

37.57 ± 6.05 (31–45)
34.14 ± 9.55 (22–54)
29.43 ± 8.50 (23–43)

PTSD, posttraumatic stress disorder; NC, normal controls; LC, light controlled.

Participants were excluded if they: a) reported current
suicidal or homicidal ideation; b) met DSM-V criteria for current
substance abuse or dependence (except nicotine or caffeine) per
self-reported answers on the diagnostic interview; or c) met
DSM-V criteria for a psychotic disorder; or d) were diagnosed
with incapacitating cognitive impairment, traumatic brain
injury; or e) were taking supplementary melatonin; or f) were
on specific medications known to alter endogenous melatonin
levels (e.g., beta blockers, methamphetamines or nonsteroidal
anti-inflammatory drugs); and/or (g) recent shift work or
transmeridian travel. Participants were asked to refrain from the
use of alcohol for 24 h prior to participation in data collection.
This investigation protocol was approved by the Defence
Research and Development Canada (DRDC) Human Research
Ethics Committee (HREC; Protocol No. 2017-023) and adhered
to the standards and regulations set forth by the Tri-Council
Policy in accordance with the Ethical Principles for Medical
Research Involving Human Subjects adopted in the Declaration
of Helsinki. All participants provided written informed consent
after a complete description of the study procedural details were
explained to them and discussing any questions or concerns
about the protocol. Participants were recruited between 2017
and 2018 by DRDC—Toronto Research Centre (TRC) nonphysician research coordinator/staff through referrals by military
physicians, mental health professionals, community clinics, and
advertisements within Canadian Forces Bases (CFB) and/or
through one of several Operational Stress Injury (OSI) clinics of
the Department of Veterans Affairs Canada (VAC).

Experimental Procedures

All participants wore a standard wrist activity monitor
(Motionlogger version 14.000, Ambulatory Monitoring Inc.,
Amherst, NY, USA) for 7 days prior to the data collection to
establish their baseline sleep hygiene. The actigraphic data were
analyzed by the Cole-Kripke algorithm (43). Parameters assessed
during the week prior to the 24-h data collection were daily
bedtimes, arise times, time in bed (min), total wake minutes,
total sleep minutes, sleep efficiency (%), Sleep LATency (SLAT),
wake after sleep onset (WASO), and # of sleep episodes (see
Supplementary Data Table 2). To assist scoring of the actigraph
data all participants maintained a daily sleep log.
On the 8th day, all participants underwent a 24-h salivary
melatonin assessment by providing 13 bi-hourly samples
commencing at 0900 h and finishing at 0900 h the next day. All saliva
samples were collected in very dim light (5 lux) since normal room
lighting levels will suppress endogenous melatonin production.
Each participant was assigned to a lounge chair for the entire 24-h
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Statistical Analyses

All demographic and clinical data in the tables are expressed as
number and percentage of subjects [N (%)] or mean and standard
deviation [mean (±SD)]. The mean (±SEM) salivary melatonin
concentrations were compared using a “group” (PTSD vs. NC
vs. LC) x “time of day” repeated-measures univariate analysis of
variance (ANOVA) using the Geisser-Greenhouse correction
for repeated measures. The mean (±SEM) of all sleep parameters
were compared using a group x day repeated-measures univariate
ANOVA to assess the effect of group and days and their interactions
on each of the sleep parameters. Post hoc comparisons of significant
effects in ANOVAs were performed using Newman-Keuls test.
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A p-value < 0.05 was considered statistically significant. Statistical
analyses were performed using STATISTICA Software Version
13, Palo Alto CA, USA.

RESULTS
Twenty-Four Hour Melatonin Production

The 24-h salivary melatonin secretion curves for all groups
are shown in Figure 1. Overall, peak salivary melatonin
concentrations (pg/ml ± SEM) were 17.9 ± 1.7, 32.3 ± 7.9, and
58.0 ± 7.0 in the PTSD, NC, and LC groups, respectively. These
peak levels occurred between 2300 and 0500 h for each of the
PTSD and NC groups and between 0100 and 0500 h for the LC
group. The 3 groups x 13 samples ANOVA indicated that the main
effect of "group" was significant F(2,18) = 7.52, p = .004 (Figure 2),
and the group x time of day interaction F(6.93,62.36) = 4.26,
p = .001 was significant (Figure 1). Post hoc testing of the group x
time of day interaction confirms that the NC group produced
more melatonin than the PTSD group between 0100 and 0500 h,
whereas the LC group produced more melatonin than either the
NC or PTSD groups between 2300 and 0700 h.
The significant main effect of group (Figure 2) indicated that
the mean 24-h melatonin production was higher in the LC group
than the PTSD and NC groups.

FIGURE 2 | Mean melatonin concentration (pg/ml) for each of three groups:
posttraumatic stress disorder (PTSD), normal controls (NC), and light
controlled (LC). All values are means ± SEM.

efficiency (80 to 90%). To achieve this sleep quality, sleep latency
should be low (generally less than 10–15 min) with minimum
WASO, and only a few sleep episodes (44).
The sleep data for all three groups (PTSD, NC, and LC) are
illustrated in Supplementary Data Table 2.
Participant 2 had the worst sleep of the PTSD group while
participant 6 had the best sleep of this group. Participant 2
averaged about 428 min (7 h and 8 min) in bed of which only
318 min (5 h and 18 min) were sleep. His mean WASO was very
high (89 min) and his sleep efficiency was low (78.10%). He also
averaged a very high number of sleep episodes (36), indicating
extremely fractured sleep. This participant was not taking
medications that facilitate sleep.
In contrast to participant 2, participant 6 had an average of 456
min (7 h and 36 min) of daily nocturnal sleep. His sleep average
efficiency was 94%, and his average sleep latency and WASO
were 11 min and 28 min, respectively. His average number of
sleep episodes was 14 (upper normal range).
On average, participant 2 took about 19 min longer to fall
asleep than participant 6. Participant 2 also spent about 60 min
longer awake after initial sleep onset and had about 23 more
sleep episodes each night than participant 6. The other PTSD
participants (numbers 1, 3, 4, 5, and 7) had sleep quality that was
intermediate between the extremes of participants 2 and 6 in all
of these parameters.

Sleep Data

Posttraumatic Stress Disorder Participants With the
Best and Worst Sleep

To sustain optimum health daily sleep should involve
approximately 8 h in bed, a regular bedtime, and normal sleep

Normal Control Participants With the Best
and Worst Sleep

FIGURE 1 | Mean melatonin concentrations (pg/ml) sampled over a 24-h
period for each of the three groups: posttraumatic stress disorder (PTSD),
normal controls (NC), and light controlled (LC). Significant differences
occurred during physiologic night (2300 to 0700 h). Shaded symbols indicate
values that are significantly (p < 0.05) different between groups: the time of
day data points where NC and LC demonstrate higher melatonin levels than
PTSD are indicated with blackened circles (NC) or blackened triangles (LC),
respectively. All values are means ± SEM.
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Participant 8 had the worst sleep of the NC group while
participant 10 had the best sleep of this group.
Participant 8 reported that his sleep was compromised
because he was studying in the evenings. His average daily time
in bed was 400 min, resulting in 324 min (5 h and 24 min) of
sleep. His sleep efficiency was quite low at 72%. While his average
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sleep latency 17 min. He averaged about 26 sleep episodes per
night, reflecting significantly fractured sleep.
Participant 10 averaged about 533 min (8 h and 53 min) in
bed, resulting in an average of 497 min (8 h and 17 min) of sleep.
His average sleep efficiency was just over 93%, while his sleep
latency and WASO were about 19 and 24 min respectively. His
average number of sleep episodes was about 10 per night and
within normal limits.
On average, participant 10 achieved about 133 min (2 h
and 13 min) more daily time in bed and achieved 173 min (2 h
and 53 min) more sleep than participant 8. Participant 10 also
had about a 21% higher sleep efficiency than participant 8. On
average, participant 8 took about 2 min longer to fall, spent about
68 min longer awake after initial sleep onset, and had about 16
more sleep episodes each night than participant 10. The other
NC participants (numbers 9, 11, 12, 14, and 15) had sleep quality
intermediate between the extremes of participants 8 and 10 in all
of these parameters.

weekend sleep behaviors of later bed times and arise times, and
increased sleep minutes.

DISCUSSION
This is the first study to measure salivary melatonin secretion
over a 24 h period in military PTSD cases versus matched
controls. The melatonin profile curve in the PTSD group showed
a blunted nocturnal peak and lower total quantity of melatonin
production relative to the healthy control groups (NC and LC).
By contrast, there was little difference in the sleep parameters
assessed between the three groups.
Since six of seven PTSD participants were either on sleeping
medications or anxiolytics that are known to facilitate sleep, the
PTSD group sleep characteristics were better than expected.
Two participants in the NC group had multiple nights with
bedtimes ranging from 0130 to 0330 h, which decreased the
average quality of the NC group sleep. The LC group (based
in the high arctic) were restricted to quarters after 2000 h for
safety due to the presence of polar bears around the CFS Alert
Station; hence, they avoided exposure to outdoor 24-7 daylight
prior to bedtime. Consequently, their sleep-wake was better
than we have measured previously in other participants at
CFS Alert during arctic summer (42). The delays in bedtime
and arise time that were evident in Saturday and Sunday (for
all three groups) simply reflected normal weekend behavior in
that there was no obligation to report to work on Saturday or
Sunday mornings.
Notwithstanding the similarity in sleep hygiene across the
three groups, there were significant differences in nocturnal
melatonin production between these groups. Both the NC and
PTSD groups produced significantly less overall daily melatonin
than the LC group (Figure 2). Despite the fact that six of the
seven PTSD participants were on medications known to counter
insomnia, it is apparent these sleeping medications did not restore
the levels of endogenous melatonin for this group. The LC group
would normally have had access to the outdoors in the arctic
summer evening, which would have suppressed their melatonin,
thus delaying their sleep pressure and hence their bedtime,
causing difficulty to arise at their normal time the following
morning. In this instance, the lack of access to the outdoors
precluded the suppression of melatonin that we have seen
previously in personnel stationed at CFS Alert during the arctic
summer. The amplitude of the nocturnal surge of melatonin in
the LC group (Figure 1) was quite normal and very similar to the
melatonin profiles that we have measured in the lower latitudes
across Canada (45). In contrast, the amplitude of the melatonin
rhythm in each of NC and PTSD groups is significantly lower. In
the case of the NC group, the lower amplitudes were probably
related to the sleep behaviors of these participants, several of
whom had substantially later bedtimes and likely late evening
light exposure as a result.
In the PTSD group, the markedly lower amplitude of the
nocturnal surge was likely associated with a pathophysiological

Light Controlled Participants With the Worst and
Best Sleep

Participant 12A had the worst sleep of the LC group, while
participant 1A had the best sleep of this group.
Participant 12A had an average bedtime of 0005 h. He
averaged about 406 min (6 h and 46 min) in bed, resulting
in an average of 379 min (6 h and 19 min) of daily sleep. His
average sleep efficiency was just over 93%, while his sleep
latency and WASO were about 10 and 18 min respectively.
His average number of sleep episodes was about 10 per night
and normal.
Participant 1A had an average bedtime of 2301 h. He averaged
about 568 min (9 h and 28 min) in bed, resulting in an average
of 513 min (8 h and 33 min) of daily sleep. His average sleep
efficiency was about 91%, while his sleep latency and WASO
were about 9 and 43 min respectively. His average number of
sleep episodes was about 16 per night, which was in the highnormal range.
On average, participant 1A achieved about 162 min (2 h and
42 min) more daily time in bed than participant 12A, achieved
134 min (2 h and 14 min) more sleep than participant 12A and
had a similar sleep efficiency (about 91 vs. 93%) as participant
12A. Both participant 1A and 12A had very similar sleep
latencies (9 vs. 10 min). Participant 1A had a higher average
WASO than participant 12A (43 min versus 88 min) and a
higher average number of daily sleep episodes (16 versus 10)
reflecting lower sleep pressure in participant 1A, since he
was well rested. The other LC participants (numbers 6A, 7A,
8A, 10A, and 11A) had a sleep quality that was intermediate
between the extremes of participants 1A and 12A in all of
these parameters.
Each of the sleep parameters shown in Supplementary
Data Table 2 were analyzed by three groups x 7 days repeatedmeasures analysis of variance. There were no group differences in
any parameter, although there were some differences across days
of the week, indicating that all three groups exhibited normal
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response to their PTSD and may signify an inability to maintain
an circadian sleep-wake rhythm (30, 46). The duration of the
nocturnal surge of endogenous melatonin in the LC group ranges
from about 2100 to 0900 h, and is also quite typical and similar to
what we have previously measured. In contrast the duration of the
nocturnal surge of endogenous melatonin for the NC and PTSD
groups was shortened. The shortened duration of the nocturnal
melatonin surge of the NC group was likely due to the nocturnal
exposure to light (of the subjects who had delayed bedtimes)
(47, 48). Similar to the reduced amplitude of melatonin, the
shortened duration of the nocturnal melatonin surge of the
PTSD group was likely a direct consequence of their PTSD as
their sleep behaviors were generally in the normal range due to
sleep facilitation medications and thus did not have late evening
light exposure (30, 46). Our findings of blunted melatonin
production in PTSD, are consistent with those of MacFarlane
et al. (30) and may explain the findings of Seyffert and Gettey
(38) that supplementary bedtime melatonin was helpful in sleep
restoration and a reduction of symptoms in their case study
of a veteran with PTSD. Pharmacotherapy, usually selective
serotonin reuptake inhibitors (SSRIs), and psychotherapy,
such as cognitive-behavioral therapy, are regarded as the firstline treatments for military PTSD (17). However, treatmentrefractory PTSD, a more severe form of the illness, has low rates
of response or remission, even after an adequate trial of SSRI
therapy (16). Thus, finding alternatives to SSRIs for treatment of
PTSD is imperative to relieve the suffering associated with this
disorder (49)
Melatonin production typically declines with age (50),
and more so in neurodegenerative diseases, such as dementia
(51). Deficiency in the production of endogenous melatonin
that results in specific functional losses are improved by
supplementation with exogenous melatonin (52). There is ample
evidence of reduced endogenous melatonin in various types
of cardiac diseases (53–57), fibromyalgia (51, 58), neuralgia
(58), migraine (59, 60), epilepsy (61, 62), Menières disease
(63), various cancers (64, 65), attention-deficit hyperactivity
disorder (66), recurrent depression (67), and bipolar disorder
(68). Agorastos and Lindhorst describe potential pleiotropic
benefits of melatonergic treatments to remediate problems
with chronodisruption, hypothalamic pituitary adrenal-axis
dysfunction, sympathoadrenal and autonomic dysregulation,
neuroimmunomodulation, oxidative stress, brain injury,
cognitive function, memory and neurocircuitry, mood and
anxiety disorders (32). The work reported here indicates that
PTSD should be added to this evolving list of disorders/diseases
that result in blunted production of endogenous melatonin,
and work investigating the efficiency of supplementation with
exogenous melatonin in PTSD sufferers should be undertaken
soonest. There is also recent evidence that long-chain
polyunsaturated fatty acids can be beneficial in attenuating PTSD
symptomology (69). These and other antioxidant strategies for
treating PTSD should also be investigated.
The results of this vanguard study must be interpreted
within the context of its limitations. We recognize that this
study suffers from a small sample size, and that larger military
cohort studies are required to expand and more conclusively

Frontiers in Psychiatry | www.frontiersin.org

confirm these initial findings. However, even with a modest
sample size of seven PTSD cases, this preliminary evidence
is quite compelling with respect to the dramatically reduced
levels of melatonin in the PTSD cohort. Similarly, our military
control sample was not ideal, since a military career and
operational requirements impacted the sleep/wake cycle of
these individuals. Future studies involving military populations
must recognize that the less than ideal sleep habits often
observed in serving military members may influence or even
confound their results for sleep parameters. Thus, investigators
may consider, as we did, strictly controlling nocturnal light
exposure, imposing daily bedtime deadlines and encouraging
sufficient daily time in bed to obtain optimal results for
melatonin production and calculation of DLMO.

CONCLUSION
Our findings reveal severely blunted nocturnal melatonin
secretion in those individuals with military-related PTSD. Based
upon these findings, further investigations through preclinical
research and clinical interventional studies are warranted. This
may include methodologically robust prospective randomized
controlled studies, assessing the efficacy of melatonin
treatment strategies in the prevention and/or treatment of
PTSD. Given the potential pleiotropic benefits of melatonergic
therapies to remediate problems with chronodisruption and
neuroimmunomodulation, melatonin treatment could provide a
potentially promising therapeutic approach with beneficial effects
in the management of PTSD and trauma-related syndromes and
comorbidities. In particular, therapeutic doses of melatonin may
be beneficial as a complementary or alternative approach in those
subgroups of combat veterans with severe sleep abnormalities and
who are refractory to commonly employed psychotherapeutic
and/or pharmacological options.
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